Stereotaxis (STXS) recently filed two shelf registrations that together cover up to about $205.3 million of common equity, highlighting potential future capital raises that could affect dilution and investor sentiment toward the stock.

The recent shelf registrations arrive during a weaker patch for Stereotaxis, with the stock closing at US$1.65 and recording a 30 day share price return down 9.34%, alongside a 1 year total shareholder return down 30.67% but a 3 year total shareholder return up 9.27%. This suggests longer term holders have seen a very mixed journey while recent momentum has been fading.

If this funding news has you thinking more broadly about opportunities in medical and automation technologies, it could be a good time to scan 32 robotics and automation stocks.

After a sharp pullback and fresh shelf registrations that point to possible future dilution, Stereotaxis now sits at US$1.65 and a crossroads. Is it worth stepping in today, or waiting for a different entry point as valuation comes into focus next?

Most Popular Narrative: 52.9% Undervalued

At a last close of $1.65 versus a narrative fair value of $3.50, Stereotaxis is framed as significantly undervalued, with that gap hinging on how its growth story plays out over time.

Although demand for MAGiC catheters currently exceeds supply and initial revenue per procedure of more than US$5,000 to roughly US$8,000 is in line with broader EP economics, reliance on a contract manufacturer, the gradual manufacturing ramp towards the targeted 500 catheters a month, and potential yield issues could delay the timing and consistency of disposable revenue growth and slow the path to better earnings.

Want to see what kind of revenue ramp and margin shift could justify that higher fair value? The narrative leans on aggressive top line growth, rising profitability and a richer future earnings multiple. The exact assumptions may surprise you.

Result: Fair Value of $3.50 (UNDERVALUED)

However, this Stereotaxis narrative could be upended if MAGiC manufacturing bottlenecks persist, or if the shift away from Johnson & Johnson prolongs customer transitions.

Another View On Stereotaxis Valuation

The SWS fair ratio points to a very different picture for Stereotaxis. The stock trades on a P/S of 5.3x, compared with an estimated fair ratio of 3.3x and an industry and peer average of 2.8x. That gap suggests investors should think hard about how much execution risk is already priced in.

Next Steps

With sentiment on Stereotaxis clearly split between concern and optimism, consider moving promptly from headline impressions to your own judgement by weighing the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Stereotaxis?

If Stereotaxis has sharpened your focus on where to put fresh capital, do not stop here. Broaden your watchlist before the next move in your portfolio passes you by.

• Target potential mispricings by reviewing companies flagged in the 49 high quality undervalued stocks.
• Strengthen your portfolio core with businesses highlighted in the solid balance sheet and fundamentals stocks screener (48 results).
• Reduce portfolio stress by considering companies featured in the 82 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.